Thursday August 2, 2012 0 commentsBOULDER - Covidien (NYSE: COV) announced the U.S. Food and Drug Administration has granted the company 510(k) clearance to market the Covidien Nellcor Bedside SpO2 Patient Monitoring System.
The clearance means the new patient monitoring system is now available for sale in the U.S., Covidien said.
The system continuously monitors SpO2 and pulse rate for adult, pediatric and neonatal patients, giving clinicians instant access to comprehensive trending respiratory information.
The technology enables clinicians to detect subtle - yet critical - heart rate and SpO2 variations earlier and address respiratory complications sooner.
"Health care professionals on the general care floor and in other lower-acuity areas of the hospital need critical patient information at their fingertips so they can respond quickly to health threats," said Robert J. White, Covidien's president of respiratory and monitoring systems.
"By giving them ready access to a patient's respiratory history, the system allows them to focus on delivering efficient, high-quality care - not gathering and managing data."
Covidien is a leading global provider of health care products, earning $11.6 billion in 2011. For more information, visit www.covidien.com.